Psoriasis 2 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

PSORS2 MCID: PSR017 MIFTS: 55	Psoriasis 2 (PSORS2) Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Psoriasis 2

MalaCards integrated aliases for Psoriasis 2:

Name: Psoriasis 2 ⁵⁷ ¹² ⁷⁴ ¹⁵ ⁷²

Psoriasis Vulgaris ⁷⁴ ⁷²

Psoriasis ⁷⁴ ⁷²

Psors2 ⁵⁷ ⁷⁴

Psoriasis, Susceptibility to, Type 2 ⁴⁰

Pv ⁷⁴

Characteristics:

OMIM:

⁵⁷

Inheritance:
autosomal dominant

Miscellaneous:
variability in age of onset and severity of disease

HPO:

³²

psoriasis 2:
Inheritance autosomal dominant inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases Immune diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0080475

OMIM ⁵⁷ 602723 PS177900

MeSH ⁴⁴ D011565

MedGen ⁴² C1864497

UMLS ⁷² C0033860 C0263361 C1864497

Sources

Summaries for Psoriasis 2

UniProtKB/Swiss-Prot : ⁷⁴ Psoriasis 2: A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

MalaCards based summary : Psoriasis 2, also known as psoriasis vulgaris, is related to skin disease and contact dermatitis, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 2 is CARD14 (Caspase Recruitment Domain Family Member 14), and among its related pathways/superpathways are T cell receptor signaling pathway and Th1 Differentiation Pathway. The drugs Esomeprazole and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are hyperkeratosis and parakeratosis

Disease Ontology : ¹² A psoriasis that has material basis in heterozygous mutation in the CARD14 gene on chromosome 17q25.

More information from OMIM: 602723 PS177900

Sources

Related Diseases for Psoriasis 2

Diseases in the Psoriasis family:

Psoriasis 1	Psoriasis 3
Psoriasis 2	Psoriasis 4
Psoriasis 5	Psoriasis 6
Psoriasis 7	Psoriasis 9
Psoriasis 8	Psoriasis 10
Psoriasis 11	Psoriasis 12
Psoriasis 13	Psoriasis 15

Diseases related to Psoriasis 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1248)

#	Related Disease	Score	Top Affiliating Genes
1	skin disease	30.4	TNF KRT16 CARD14
2	contact dermatitis	29.9	TNF KRT16
3	lichen planus	29.9	TNF KRT16
4	pustular psoriasis	29.8	TNF CARD14
5	irritant dermatitis	29.4	TNF KRT16
6	chronic graft versus host disease	29.3	TNF CD4
7	acquired immunodeficiency syndrome	29.3	TNF CD4
8	human immunodeficiency virus infectious disease	29.2	TNF CD4
9	psoriasis	28.8	TNF KRT16 CARD14
10	pneumocystosis	28.8	TNF CD4
11	melkersson-rosenthal syndrome	28.7	TNF CD4
12	guttate psoriasis	12.7
13	psoriasis 15, pustular	12.6
14	psoriasis 4	12.6
15	psoriasis 3	12.6
16	psoriasis 10	12.6
17	psoriasis 6	12.5
18	psoriasis 5	12.5
19	psoriasis 12	12.5
20	psoriasis 8	12.5
21	psoriasis 9	12.5
22	psoriasis 15	12.5
23	polycythemia vera	12.4
24	mental retardation and psoriasis	12.3
25	pustulosis palmaris et plantaris	12.3
26	tranebjaerg svejgaard syndrome	12.1
27	psoriatic juvenile idiopathic arthritis	11.9
28	psoriasis 1	11.9
29	impetigo herpetiformis	11.8
30	juvenile rheumatoid arthritis	11.6
31	geographic tongue	11.6
32	pemphigus	11.5
33	parapsoriasis	11.5
34	pemphigus vulgaris, familial	11.5
35	arthritis	11.5
36	persistent vegetative state	11.5
37	pulmonary valve stenosis	11.5
38	spondyloarthropathy 1	11.5
39	vitiligo-associated multiple autoimmune disease susceptibility 1	11.5
40	psoriasis 14, pustular	11.5
41	subacute cutaneous lupus erythematosus	11.4
42	chronic recurrent multifocal osteomyelitis	11.4
43	temporomandibular ankylosis	11.4
44	singleton-merten syndrome 1	11.2
45	systemic onset juvenile idiopathic arthritis	11.2
46	variegate porphyria	11.2
47	psoriasis 7	11.2
48	psoriasis 11	11.2
49	psoriasis 13	11.2
50	nail disorder, nonsyndromic congenital, 1	11.1

Graphical network of the top 20 diseases related to Psoriasis 2:

Sources

Symptoms & Phenotypes for Psoriasis 2

Human phenotypes related to Psoriasis 2:

³²

#	Description	HPO Source Accession
1	hyperkeratosis ³²	HP:0000962
2	parakeratosis ³²	HP:0001036
3	scaling skin ³²	HP:0040189
4	psoriasiform dermatitis ³²	HP:0003765
5	epidermal acanthosis ³²	HP:0025092

Symptoms via clinical synopsis from OMIM:

⁵⁷

Skin Nails Hair Skin Histology:
hyperkeratosis
parakeratosis
epidermal acanthosis
follicular plugging
alternating orthokeratosis and parakeratosis (in some patients)
more

Skin Nails Hair Skin:
plaque-like scaling skin lesions
erythrodermic psoriasis (in some patients)
pustular psoriasis (in some patients)
skin atrophy, diffuse, in older patients

Skeletal:
arthritis, psoriatic (in some patients)

Clinical features from OMIM:

602723

UMLS symptoms related to Psoriasis 2:

pruritus, exanthema, psoriasiform rash

Sources

Drugs & Therapeutics for Psoriasis 2

Drugs for Psoriasis 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 466)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Esomeprazole

Approved, Investigational

Phase 4

119141-88-7, 161796-78-7, 161973-10-0

9568614 4594

Dapsone

Approved, Investigational

Phase 4

80-08-0

2955

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

5754

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Clobetasol

Approved, Experimental, Investigational

Phase 4

25122-46-7, 25122-41-2

32798 5311051

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4

93-14-1

3516

carbamide peroxide

Approved

Phase 4

124-43-6

Fluticasone

Approved, Experimental

Phase 4

90566-53-3

62924

Clocortolone

Approved

Phase 4

34097-16-0, 4828-27-7

5282493 5311052

Mannitol

Approved, Investigational

Phase 4

69-65-8

453 6251

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

Orange

Approved

Phase 4

Strawberry

Approved

Phase 4

Artichoke

Approved

Phase 4

Sorafenib

Approved, Investigational

Phase 4

284461-73-0

216239 406563

Tofacitinib

Approved, Investigational

Phase 4

477600-75-2

Adalimumab

Approved

Phase 4

331731-18-1

16219006

Zinc

Approved, Investigational

Phase 4

7440-66-6

32051

Desoximetasone

Approved

Phase 4

382-67-2

5311067

Certolizumab pegol

Approved

Phase 4

428863-50-7

Mercaptopurine

Approved

Phase 4

50-44-2

667490

Aspirin

Approved, Vet_approved

Phase 4

50-78-2

2244

Sotalol

Approved

Phase 4

959-24-0, 3930-20-9

5253

tannic acid

Approved

Phase 4

1401-55-4

Benzocaine

Approved, Investigational

Phase 4

94-09-7, 1994-09-7

2337

Ixekizumab

Approved, Investigational

Phase 4

1143503-69-8

Metformin

Approved

Phase 4

657-24-9

4091 14219

Ustekinumab

Approved, Investigational

Phase 4

815610-63-0

Vedolizumab

Approved

Phase 4

943609-66-3

Betamethasone

Approved, Vet_approved

Phase 4

378-44-9

9782

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Salicylic acid

Approved, Investigational, Vet_approved

Phase 4

69-72-7

338

Capsaicin

Approved

Phase 4

404-86-4

1548943

Vitamin A

Approved, Nutraceutical, Vet_approved

Phase 4

22737-96-8, 11103-57-4, 68-26-8

9904001 445354

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Glycine

Approved, Nutraceutical, Vet_approved

Phase 4

56-40-6

750

Calcium

Approved, Nutraceutical

Phase 4

7440-70-2

271

Calcitriol

Approved, Nutraceutical

Phase 4

32222-06-3

5280453 134070

Retinol palmitate

Phase 4

retinol

Phase 4

Antiparasitic Agents

Phase 4

Antiprotozoal Agents

Phase 4

Antimalarials

Phase 4

Hydrocortisone 17-butyrate 21-propionate

Phase 4

Hydrocortisone hemisuccinate

Phase 4

Hydrocortisone-17-butyrate

Phase 4

Chlorpheniramine, phenylpropanolamine drug combination

Phase 4

Omega 3 Fatty Acid

Phase 4

Chelating Agents

Phase 4

Tin Fluorides

Phase 4

Interventional clinical trials:

(show top 50) (show all 1555)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris	Unknown status	NCT01443338	Phase 4	Triptergium Wilfordii;Acitretin
2	The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris	Unknown status	NCT01088165	Phase 4	Adalimumab treatment arm;Fumaric acid esters treatment group
3	An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability	Unknown status	NCT01228409	Phase 4	Acitretin 17.5 mg/day
4	Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study.	Unknown status	NCT02248792	Phase 4	Methotrexate
5	The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab)	Unknown status	NCT02693470	Phase 4	Ustekinumab
6	Proton Pump Inhibitors Use in Patients With Psoriasis	Unknown status	NCT02624544	Phase 4	esomeprazole;desonide
7	Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis	Unknown status	NCT00707070	Phase 4	efalizumab plus placebo;efalizumab plus acitretin
8	Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study.	Unknown status	NCT03263624	Phase 4	Tazarotene Cream 0.1%
9	An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use	Unknown status	NCT01132235	Phase 4
10	Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study	Unknown status	NCT01439425	Phase 4
11	A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis	Unknown status	NCT01558310	Phase 4	Ustekinumab;Placebo
12	Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy	Unknown status	NCT01237262	Phase 4	Adalimumab, etanercept, infliximab
13	Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis	Unknown status	NCT01223976	Phase 4
14	The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals	Unknown status	NCT01405352	Phase 4
15	A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome	Unknown status	NCT02550080	Phase 4	Dapsone
16	A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris	Completed	NCT00248456	Phase 4	Calcipotriol plus betamethasone dipropionate ointment
17	A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris.	Completed	NCT02733874	Phase 4	Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
18	Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris	Completed	NCT00216892	Phase 4	Calcipotriol, (calcipotriol + betamethasone)
19	Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population	Completed	NCT02533973	Phase 4	Xamiol® gel;Daivonex® scalp solution
20	Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris	Completed	NCT02004574	Phase 4	Calcipotriol/betamethasone dipropionate gel
21	A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis	Completed	NCT03331835	Phase 4	Fumaric acid esters
22	A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris	Completed	NCT00640393	Phase 4	Etanercept
23	Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris	Completed	NCT01707043	Phase 4	Taclonex
24	A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy	Completed	NCT01761019	Phase 4	Taclonex Topical Suspension
25	An Investigator-Initiated, Assessor Blinded, Randomized Study Comparing the Mechanism of Action of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis.	Completed	NCT00932113	Phase 4	Methotrexate;Adalimumab (Humira)
26	Study to Evaluate Resistant Disease/Max Adherence to Topical Treatments in Patients With Atopic Dermatitis and Psoriasis	Completed	NCT03050294	Phase 4	Desoximetasone 0.25% spray
27	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis	Completed	NCT00791765	Phase 4
28	A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis	Completed	NCT00195507	Phase 4	Etanercept
29	Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis	Completed	NCT00332332	Phase 4
30	A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis	Completed	NCT00663052	Phase 4	Etanercept;Etanercept
31	Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%	Completed	NCT01893567	Phase 4	Clobex Spray
32	A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy	Completed	NCT00161655	Phase 4	Etanercept;Methotrexate
33	A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy	Completed	NCT00581555	Phase 4	Etanercept
34	Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial	Completed	NCT02313922	Phase 4	etanercept combined with methotrexate or etanercept combined with placebo
35	An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept	Completed	NCT00493324	Phase 4	alefacept;polyvalent pneumococcal vaccine
36	Elocon vs Fluticasone in Localized Psoriasis	Completed	NCT00763529	Phase 4	Mometasone;Fluticasone
37	Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis	Completed	NCT00669123	Phase 4	Chondroitin sulphate;Placebo
38	Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept	Completed	NCT00581165	Phase 4	Etanercept
39	Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis	Completed	NCT00658606	Phase 4	alefacept
40	An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis	Completed	NCT02985736	Phase 4	Topicort Topical Spray
41	A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis	Completed	NCT00287118	Phase 4	Efalizumab
42	An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days	Completed	NCT01714544	Phase 4	Cloderm Cream
43	Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab	Completed	NCT00967538	Phase 4	etanercept 50 mg
44	An Open Label, Non-comparative, Multicentre, Phase IV Study to Evaluate the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis	Completed	NCT01373567	Phase 4	TINEFCON
45	A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI)	Completed	NCT01511315	Phase 4	Ustekinumab
46	A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis	Completed	NCT00842153	Phase 4	Clobetasol propionate foam;Vehicle foam
47	A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis	Completed	NCT02274792	Phase 4	Etanercept
48	A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS	Completed	NCT02187172	Phase 4	Ustekinumab;Placebo
49	A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis	Completed	NCT00110981	Phase 4	Etanerept;Etanercept
50	A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects.	Completed	NCT00852761	Phase 4	Olux-E Foam;Clobex lotion

Search NIH Clinical Center for Psoriasis 2

Inferred drug relations via UMLS ⁷² / NDF-RT ⁵¹ :

Acitretin

alefacept

Aloe vera preparation

Anthralin

ANTHRALIN PWDR

Betamethasone

Betamethasone acetate

Betamethasone benzoate

betamethasone dipropionate

betamethasone sodium phosphate

Betamethasone valerate

BETAMETHASONE VALERATE PWDR

calcipotriene

Calcitriol

Cholecalciferol

Coal Tar

Coal tar extract

Coal tar pitch volatiles

COAL TAR,COLLOIDAL

COAL TAR,REFINED

Cod Liver Oil

Colloid sulfur

Cyclosporine

Etretinate

Fish Liver Oils

fluocinolone

Fluocinolone Acetonide

hydroxyurea

Methotrexate

Methotrexate Sodium

Methoxsalen

mycophenolate mofetil

mycophenolate mofetil hydrochloride

Salicylic Acid

SALICYLIC ACID PWDR

Sulfur

SULFUR PWDR

SULFUR,COLLOIDAL

tazarotene

Thioguanine

Trioxsalen

Sources

Genetic Tests for Psoriasis 2

Sources

Anatomical Context for Psoriasis 2

MalaCards organs/tissues related to Psoriasis 2:

⁴¹

Skin, Testes, T Cells, Endothelial, Bone, Liver, Monocytes

Sources

Publications for Psoriasis 2

Articles related to Psoriasis 2:

(show top 50) (show all 80)

#	Title	Authors	PMID	Year
1	Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. ³⁸ ⁸ ⁷¹	Jordan CT...Bowcock AM	22521419	2012
2	PSORS2 is due to mutations in CARD14. ³⁸ ⁸ ⁷¹	Jordan CT...Bowcock AM	22521418	2012
3	Mapping of psoriasis to 17q terminus. ⁸ ⁷¹	Hwu WL...Chen YT	15689454	2005
4	Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. ⁸ ⁷¹	Tomfohrde J...Menter A	8178173	1994
5	PSORS2 markers are not associated with psoriatic arthritis in the Italian population. ³⁸ ⁸	Giardina E...Novelli G	16733365	2006
6	Genetic analysis of PSORS2 markers in a UK dataset supports the association between RAPTOR SNPs and familial psoriasis. ³⁸ ⁸	Capon F...Trembath RC	15173233	2004
7	A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. ³⁸ ⁸	Helms C...Bowcock AM	14608357	2003
8	Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. ³⁸ ⁸	Speckman RA...Bowcock AM	12483297	2003
9	Mutations in IL36RN in patients with generalized pustular psoriasis. ⁷¹	Korber A...Huffmeier U	23648549	2013
10	A promoter sequence variant of ZNF750 is linked with familial psoriasis. ⁷¹	Yang CF...Chen YT	18256691	2008
11	Analysis of RUNX1 binding site and RAPTOR polymorphisms in psoriasis: no evidence for association despite adequate power and evidence for linkage. ⁸	Stuart P...Elder JT	15923274	2006
12	Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. ⁸	Enlund F...Swanbeck G	9858851	1999
13	Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. ⁸	Nair RP...Elder JT	9259283	1997
14	Confirmation of genetic heterogeneity in familial psoriasis. ⁸	Matthews D...Williamson R	7562968	1995
15	Scanning chromosome 17 for psoriasis susceptibility: lack of evidence for a distal 17q locus. ⁸	Nair RP...Elder JT	7558055	1995
16	Sustained Efficacy of Secukinumab in Subjects with Moderate-to-Severe Palmoplantar Psoriasis: 2·5-Year Results from GESTURE, a Randomized, Double-blind, Placebo-controlled Trial. ³⁸	Gottlieb AB...Frueh JA	31286480	2019
17	The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. ³⁸	Pilon D...Lefebvre P	30523738	2019
18	Epidemiology and dermatological comorbidity of seborrhoeic dermatitis: population-based study in 161 269 employees. ³⁸	Zander N...Augustin M	30802934	2019
19	Using Neural Networks for Diagnosing in Dermatology. ³⁸	Bobrova M...Kopanitsa G	31156118	2019
20	Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition. ³⁸	Dash RP...Srinivas NR	28489480	2018
21	TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. ³⁸	Conrad C...Gilliet M	29295985	2018
22	Clinical and Genetic Heterogeneity of CARD14 Mutations in Psoriatic Skin Disease. ³⁸	Israel L...Mellett M	30386326	2018
23	National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference. ³⁸	Afifi L...Liao W	28825055	2017
24	CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. ³⁸	Coppola N...Rossi F	27476469	2016
25	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. ³⁸	Papp KA...Ports WC	27716172	2016
26	Photodynamic therapy effect on cell growth inhibition induced by Radachlorin and toluidine blue O on Staphylococcus aureus and Escherichia coli: An in vitro study. ³⁸	Fekrazad R...Vand SM	27435750	2016
27	Sarcoidosis associated with psoriasis: 2 disease entities, one pathogenic pathway. ³⁸	Santalla Martinez M...Loureiro Martinez M	26947525	2016
28	[Clinical analysis of cutaneous manifestations and related factors in patients with ulcerative colitis]. ³⁸	Tian Y...Liu XG	27373283	2016
29	Use of biologics for psoriasis in Central and Eastern European countries. ³⁸	Rencz F...Gulacsi L	26370506	2015
30	The routine use of iron stain for biopsies of dermatoses of the legs. ³⁸	Northcutt AD...Tschen JA	24517257	2015
31	Generalized pustular psoriasis following allogeneic stem cell transplantation. ³⁸	George L...Pulimood SA	25472781	2015
32	Immunohistochemical expression of MCM2 in nonmelanoma epithelial skin cancers. ³⁸	Abdou AG...Eldien DS	24936676	2014
33	Metabolic syndrome in patients with psoriasis: A comparative study. ³⁸	Lakshmi S...Udayashankar C	24860744	2014
34	CARD14 expression in dermal endothelial cells in psoriasis. ³⁸	Harden JL...Lowes MA	25369198	2014
35	SNP rs11652075 in the CARD14 gene as a risk factor for psoriasis (PSORS2) in a Spanish cohort. ³⁸	Gonzalez-Lara L...Coto E	23905699	2013
36	Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. ³⁸	Maneiro JR...Gomez-Reino JJ	23797343	2013
37	A review of the clinical variants and the management of psoriasis. ³⁸	Ladizinski B...Sibbald RG	23669329	2013
38	Genome-wide linkage scan for psoriasis susceptibility loci in multiplex Tunisian families. ³⁸	Ammar M...Bowcock AM	23013406	2013
39	[Molecular identification of the PSORS2 locus: mutations and polymorphisms in CARD14 gene]. ³⁸	Dereure O	23328365	2013
40	A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. ³⁸	Strober BE...Young M	23205325	2012
41	Obesity and the risk of psoriatic arthritis: a population-based study. ³⁸	Love TJ...Choi HK	22586165	2012
42	Role of cellular oxidative stress and cytochrome c in the pathogenesis of psoriasis. ³⁸	Gabr SA...Al-Ghadir AH	22421888	2012
43	Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. ³⁸	Perman MJ...Lucky AW	21995665	2012
44	Familial pityriasis rubra pilaris is caused by mutations in CARD14. ³⁸	Fuchs-Telem D...Sprecher E	22703878	2012
45	Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. ³⁸	Langan SM...Gelfand JM	22113483	2012
46	Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. ³⁸	Augustin M...Schafer I	21623753	2011
47	Vitamin D status in psoriasis patients during different treatments with phototherapy. ³⁸	Osmancevic A...Krogstad AL	20579901	2010
48	Excimer laser for psoriasis: a review of theories regarding enhanced efficacy over traditional UVB phototherapy. ³⁸	Zakarian K...Koo J	17763609	2007
49	Diagnostic dilemma: crusted scabies superimposed on psoriatic erythroderma in a patient with acquired immunodeficiency syndrome. ³⁸	Fuchs BS...Rudikoff D	17483659	2007
50	Seborrhea-like dermatitis with psoriasiform elements caused by a mutation in ZNF750, encoding a putative C2H2 zinc finger protein. ³⁸	Birnbaum RY...Birk OS	16751772	2006

Sources

Genes for Psoriasis 2

Genes related to Psoriasis 2 (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CARD14	Caspase Recruitment Domain Family Member 14	Protein Coding	1227.64	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative variation ⁷⁴ GeneCards inferred via : Disorders Variants (show sections)	8178173 23648549 15689454 (more) 18256691 22521418 22521419
2	KRT16	Keratin 16	Protein Coding	16.26	GeneCards inferred via : Publications (show sections)
3	TNF	Tumor Necrosis Factor	Protein Coding	13.43	DISEASES inferred ¹⁵
4	CD4	CD4 Molecule	Protein Coding	13.33	DISEASES inferred ¹⁵

Sources

Variations for Psoriasis 2

ClinVar genetic disease variations for Psoriasis 2:

⁶ (show top 50) (show all 141)

#	Gene	Variation	Type	Significance	SNP ID	GRCh37 Pos	GRCh38 Pos
1	CARD14	NM_001366385.1(CARD14): c.349G> A (p.Gly117Ser)	single nucleotide variant	Pathogenic	rs281875215	17:78156589-78156589	17:80182790-80182790
2	CARD14	NM_001366385.1(CARD14): c.349+5G> A	single nucleotide variant	Pathogenic	rs587777763	17:78156594-78156594	17:80182795-80182795
3	CARD14	NM_001366385.1(CARD14): c.425A> G (p.Glu142Gly)	single nucleotide variant	Pathogenic	rs281875213	17:78157787-78157787	17:80183988-80183988
4	CARD14	NM_001366385.1(CARD14): c.424G> A (p.Glu142Lys)	single nucleotide variant	Pathogenic	rs281875212	17:78157786-78157786	17:80183987-80183987
5	CARD14	NM_001366385.1(CARD14): c.1778T> A (p.Ile593Asn)	single nucleotide variant	Uncertain significance	rs281875220	17:78172317-78172317	17:80198518-80198518
6	CARD14	NM_001366385.1(CARD14): c.536G> A (p.Arg179His)	single nucleotide variant	Uncertain significance	rs199517469	17:78157898-78157898	17:80184099-80184099
7	CARD14	NM_001366385.1(CARD14): c.1805C> T (p.Ser602Leu)	single nucleotide variant	Uncertain significance	rs201285077	17:78172344-78172344	17:80198545-80198545
8	CARD14	NM_001366385.1(CARD14): c.2483G> A (p.Arg828Gln)	single nucleotide variant	Uncertain significance	rs147592804	17:78178918-78178918	17:80205119-80205119
9	CARD14	NM_001366385.1(CARD14): c.2606A> G (p.Gln869Arg)	single nucleotide variant	Uncertain significance	rs529691290	17:78179366-78179366	17:80205567-80205567
10	CARD14	NM_001366385.1(CARD14): c.2641G> A (p.Gly881Arg)	single nucleotide variant	Uncertain significance	rs548495951	17:78179401-78179401	17:80205602-80205602
11	CARD14	NM_001366385.1(CARD14): c.589G> A (p.Glu197Lys)	single nucleotide variant	Uncertain significance	rs200790561	17:78157951-78157951	17:80184152-80184152
12	CARD14	NM_001366385.1(CARD14): c.881C> T (p.Ala294Val)	single nucleotide variant	Uncertain significance	rs139466192	17:78163589-78163589	17:80189790-80189790
13	CARD14	NM_001366385.1(CARD14): c.299A> G (p.Tyr100Cys)	single nucleotide variant	Uncertain significance	rs552779505	17:78156539-78156539	17:80182740-80182740
14	CARD14	NM_001366385.1(CARD14): c.556G> A (p.Ala186Thr)	single nucleotide variant	Uncertain significance	rs190213582	17:78157918-78157918	17:80184119-80184119
15	CARD14	NM_001366385.1(CARD14): c.2191G> A (p.Ala731Thr)	single nucleotide variant	Uncertain significance	rs537086902	17:78176191-78176191	17:80202392-80202392
16	CARD14	NM_001366385.1(CARD14): c.203T> C (p.Met68Thr)	single nucleotide variant	Uncertain significance	rs773633754	17:78155440-78155440	17:80181641-80181641
17	CARD14	NM_001366385.1(CARD14): c.1759G> A (p.Gly587Ser)	single nucleotide variant	Uncertain significance	rs146855402	17:78172298-78172298	17:80198499-80198499
18	CARD14	NM_001366385.1(CARD14): c.2314C> T (p.Arg772Cys)	single nucleotide variant	Uncertain significance	rs577478029	17:78178056-78178056	17:80204257-80204257
19	CARD14	NM_001366385.1(CARD14): c.2888C> T (p.Ala963Val)	single nucleotide variant	Uncertain significance	rs1176488460	17:78182017-78182017	17:80208218-80208218
20	CARD14	NM_001366385.1(CARD14): c.234G> T (p.Lys78Asn)	single nucleotide variant	Uncertain significance	rs143747620	17:78156474-78156474	17:80182675-80182675
21	CARD14	NM_001366385.1(CARD14): c.1370C> T (p.Ser457Leu)	single nucleotide variant	Uncertain significance	rs776782295	17:78169003-78169003	17:80195204-80195204
22	CARD14	NM_001366385.1(CARD14): c.1288C> T (p.Arg430Trp)	single nucleotide variant	Uncertain significance	rs142895605	17:78166350-78166350	17:80192551-80192551
23	CARD14	NM_001366385.1(CARD14): c.1356+4C> T	single nucleotide variant	Uncertain significance	rs373428751	17:78166422-78166422	17:80192623-80192623
24	CARD14	NM_001366385.1(CARD14): c.1046C> T (p.Ala349Val)	single nucleotide variant	Uncertain significance		17:78164655-78164655	17:80190856-80190856
25	CARD14	NM_001366385.1(CARD14): c.1211G> T (p.Arg404Leu)	single nucleotide variant	Uncertain significance		17:78165243-78165243	17:80191444-80191444
26	CARD14	NM_001366385.1(CARD14): c.1471G> A (p.Asp491Asn)	single nucleotide variant	Uncertain significance		17:78169104-78169104	17:80195305-80195305
27	CARD14	NM_024110.4(CARD14): c.1658+9_1658+11delCAG	deletion	Uncertain significance		17:78171970-78171972	17:80198171-80198173
28	CARD14	NM_001366385.1(CARD14): c.1828C> T (p.Arg610Cys)	single nucleotide variant	Uncertain significance		17:78172367-78172367	17:80198568-80198568
29	CARD14	NM_001366385.1(CARD14): c.1977C> T (p.Asp659=)	single nucleotide variant	Uncertain significance		17:78175668-78175668	17:80201869-80201869
30	CARD14	NM_001366385.1(CARD14): c.2315G> A (p.Arg772His)	single nucleotide variant	Uncertain significance		17:78178057-78178057	17:80204258-80204258
31	CARD14	NM_001366385.1(CARD14): c.545G> A (p.Arg182His)	single nucleotide variant	Uncertain significance		17:78157907-78157907	17:80184108-80184108
32	CARD14	NM_001366385.1(CARD14): c.615T> C (p.Tyr205=)	single nucleotide variant	Uncertain significance		17:78157977-78157977	17:80184178-80184178
33	CARD14	NM_001366385.1(CARD14): c.778G> A (p.Gly260Arg)	single nucleotide variant	Uncertain significance		17:78162278-78162278	17:80188479-80188479
34	CARD14	NM_001366385.1(CARD14): c.827C> A (p.Ser276Ter)	single nucleotide variant	Uncertain significance		17:78162327-78162327	17:80188528-80188528
35	CARD14	NM_001366385.1(CARD14): c.1927C> T (p.Leu643Phe)	single nucleotide variant	Uncertain significance		17:78175618-78175618	17:80201819-80201819
36	CARD14	NM_001366385.1(CARD14): c.2279G> A (p.Arg760His)	single nucleotide variant	Uncertain significance		17:78177680-78177680	17:80203881-80203881
37	CARD14	NM_001366385.1(CARD14): c.843+1G> T	single nucleotide variant	Uncertain significance		17:78162344-78162344	17:80188545-80188545
38	CARD14	NM_001366385.1(CARD14): c.2353C> T (p.Arg785Cys)	single nucleotide variant	Uncertain significance		17:78178095-78178095	17:80204296-80204296
39	CARD14	NM_001366385.1(CARD14): c.2476C> T (p.Arg826Trp)	single nucleotide variant	Uncertain significance		17:78178911-78178911	17:80205112-80205112
40	CARD14	NM_001366385.1(CARD14): c.2517G> C (p.Lys839Asn)	single nucleotide variant	Uncertain significance		17:78178952-78178952	17:80205153-80205153
41	CARD14	NM_001366385.1(CARD14): c.131G> A (p.Arg44His)	single nucleotide variant	Uncertain significance		17:78155368-78155368	17:80181569-80181569
42	CARD14	NM_001366385.1(CARD14): c.937G> A (p.Val313Met)	single nucleotide variant	Uncertain significance		17:78163645-78163645	17:80189846-80189846
43	CARD14	NM_001366385.1(CARD14): c.963+6G> A	single nucleotide variant	Uncertain significance		17:78163677-78163677	17:80189878-80189878
44	CARD14	NM_001366385.1(CARD14): c.1330G> A (p.Asp444Asn)	single nucleotide variant	Uncertain significance		17:78166392-78166392	17:80192593-80192593
45	CARD14	NM_001366385.1(CARD14): c.1652C> T (p.Ser551Leu)	single nucleotide variant	Uncertain significance		17:78171955-78171955	17:80198156-80198156
46	CARD14	NM_001366385.1(CARD14): c.1901C> T (p.Thr634Met)	single nucleotide variant	Uncertain significance		17:78175592-78175592	17:80201793-80201793
47	CARD14	NM_001366385.1(CARD14): c.2786_2788AGA[1] (p.Lys930del)	short repeat	Uncertain significance		17:78180866-78180868	17:80207067-80207069
48	CARD14	NM_001366385.1(CARD14): c.35C> T (p.Thr12Met)	single nucleotide variant	Uncertain significance		17:78155272-78155272	17:80181473-80181473
49	CARD14	NM_001366385.1(CARD14): c.40C> G (p.Leu14Val)	single nucleotide variant	Uncertain significance		17:78155277-78155277	17:80181478-80181478
50	CARD14	NM_001366385.1(CARD14): c.94C> T (p.Arg32Cys)	single nucleotide variant	Uncertain significance		17:78155331-78155331	17:80181532-80181532

UniProtKB/Swiss-Prot genetic disease variations for Psoriasis 2:

⁷⁴

#	Symbol	AA change	Variation ID	SNP ID
1	CARD14	p.Gly117Ser	VAR_068224	rs281875215
2	CARD14	p.Glu138Ala	VAR_068225	rs281875214
3	CARD14	p.Glu142Gly	VAR_068226	rs281875213
4	CARD14	p.Glu142Lys	VAR_068227	rs281875212
5	CARD14	p.Leu150Arg	VAR_068228	rs146214639
6	CARD14	p.Arg69Trp	VAR_078583	rs375624435
7	CARD14	p.Glu197Lys	VAR_078588	rs200790561

Sources

Expression for Psoriasis 2

Search GEO for disease gene expression data for Psoriasis 2.

Sources

Pathways for Psoriasis 2

Pathways related to Psoriasis 2 according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	T cell receptor signaling pathway ³⁷ Show member pathways PD-L1 expression and PD-1 checkpoint pathway in cancer ³⁷ T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.02	TNF CD4
2	Th1 Differentiation Pathway ⁶⁵ Show member pathways IL27-mediated signaling events ¹ Th17 Differentiation Pathway ⁶⁵	11.57	TNF CD4
3	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	11.5	TNF CD4
4	Hematopoietic cell lineage ³⁷	11.39	TNF CD4
5	NF-kappa B signaling pathway ³⁷	11.38	TNF CARD14
6	Innate Lymphoid Cell Differentiation Pathways ⁶⁵	11.22	TNF CD4
7	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.13	TNF CD4
8	NF-kB (NFkB) Pathway ⁶⁷	11.01	TNF CD4
9	Apoptosis-related network due to altered Notch3 in ovarian cancer ¹	10.69	TNF CARD14
10	Cytokines and Inflammatory Response ¹	10.09	TNF CD4

Sources

GO Terms for Psoriasis 2

Cellular components related to Psoriasis 2 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane raft	GO:0045121	8.62	TNF CD4

Biological processes related to Psoriasis 2 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.37	TNF CD4
2	positive regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043123	9.32	TNF CD4
3	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.26	TNF CARD14
4	tumor necrosis factor-mediated signaling pathway	GO:0033209	9.16	TNF CARD14
5	positive regulation of protein kinase activity	GO:0045860	8.96	TNF CD4
6	positive regulation of protein phosphorylation	GO:0001934	8.8	TNF CD4 CARD14

Sources

Sources for Psoriasis 2

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia

Psoriasis 2 (PSORS2)

Aliases & Classifications for Psoriasis 2

MalaCards integrated aliases for Psoriasis 2:

Characteristics:

OMIM:

HPO:

Classifications:

External Ids:

Summaries for Psoriasis 2

Related Diseases for Psoriasis 2

Diseases in the Psoriasis family:

Diseases related to Psoriasis 2 via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Psoriasis 2:

Symptoms & Phenotypes for Psoriasis 2

Human phenotypes related to Psoriasis 2:

Symptoms via clinical synopsis from OMIM:

Clinical features from OMIM:

UMLS symptoms related to Psoriasis 2:

Drugs & Therapeutics for Psoriasis 2

Drugs for Psoriasis 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Genetic Tests for Psoriasis 2

Anatomical Context for Psoriasis 2

MalaCards organs/tissues related to Psoriasis 2:

Publications for Psoriasis 2

Articles related to Psoriasis 2:

Genes for Psoriasis 2

Genes related to Psoriasis 2 (1 elite genes):

Variations for Psoriasis 2

ClinVar genetic disease variations for Psoriasis 2:

UniProtKB/Swiss-Prot genetic disease variations for Psoriasis 2:

Expression for Psoriasis 2

Pathways for Psoriasis 2

Pathways related to Psoriasis 2 according to GeneCards Suite gene sharing:

GO Terms for Psoriasis 2

Cellular components related to Psoriasis 2 according to GeneCards Suite gene sharing:

Biological processes related to Psoriasis 2 according to GeneCards Suite gene sharing:

Sources for Psoriasis 2

Inferred drug relations via UMLS ⁷² / NDF-RT ⁵¹ :